Table 1 Demographic and clinical characteristics of TOHVHP HCV group and the general population
Variable | TOHVHP HCV group | General population | p-value |
|---|---|---|---|
N = 1209 | N = 6045 | ||
N(%) | N(%) | ||
Age (yrs) (mean, SD) | 54.54 ± 11.42 | 54.54 ± 11.41 | 1.00 |
Age (yrs) (median, IQR) | 56 (49–62) | 56 (49–62) | 1.00 |
Age category | |||
 16–25 | 15 (1.2%) | 75 (1.2%) | 1.00 |
 26–35 | 77 (6.4%) | 385 (6.4%) |  |
 36–45 | 127 (10.5%) | 635 (10.5%) |  |
 46–55 | 369 (30.5%) | 1845 (30.5%) |  |
 56–65 | 464 (38.4%) | 2320 (38.4%) |  |
 66–75 | 122 (10.1%) | 610 (10.1%) |  |
 75+ | 35 (2.9%) | 175 (2.9%) |  |
Sex | 1.00 | ||
 Male | 782 (64.7%) | 3910 (64.7%) |  |
 Female | 427 (35.3%) | 2135 (35.3%) |  |
Immigration status | 0.49 | ||
 Canadian citizen | 1056 (87.3%) | 5290 (87.5%) |  |
 Immigrant from HCV endemic country | 54 (4.5%) | 230 (3.8%) |  |
 Immigrant from non-endemic country | 99 (8.2%) | 525 (8.7%) |  |
HCV mono-infection | 1151 (95.2%) | – |  |
HCV-HIV co-infection | 53 (4.4%) | – |  |
HCV-HBV co-infection | 6 (0.5%) | – |  |
Time from HCV diagnosis | |||
  < 5 years from index date | 124 (10.3%) | – |  |
 5 to < 10 years from index date | 123 (10.2%) | – |  |
 10+ years from index date | 263 (21.8%) | – |  |
 Missing | 699 (57.8%) | – |  |
Treatment statusa | |||
 Treated and cured | 690 (57.1%) | – |  |
 Treated and not cured | 51 (4.2%) | – |  |
 Never treated | 329 (27.2%) | – |  |
 Missing | 139 (11.4%) |  |  |
HCV treatment type (n = 741) | |||
 Direct acting antiviral (DAA) | 563 (76.0%) | – |  |
 Interferon (IFN) | 178 (24.0%) | – |  |
Highest fibrosis score | |||
 1 | 332 (27.5%) | – |  |
 2 | 171 (14.1%) | – |  |
 3 | 120 (9.9%) | – |  |
 4 | 309 (25.6%) | – |  |
 Missing | 277 (22.9%) | – |  |
Prevalence of multimorbidity (at least two physical conditions) | 361 (29.9%) | 1259 (20.8%) | < 0.001 |
Prevalence of physical-mental health multimorbidity | 299 (24.7%) | 574 (9.5%) | < 0.001 |